Collegium Pharmaceutical Inc (COLL)
34.25
+0.43
(+1.27%)
USD |
NASDAQ |
May 24, 16:00
34.98
+0.73
(+2.13%)
After-Hours: 20:00
Collegium Pharmaceutical Enterprise Value: 1.426B for May 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 24, 2024 | 1.426B |
| May 23, 2024 | 1.412B |
| May 22, 2024 | 1.423B |
| May 21, 2024 | 1.434B |
| May 20, 2024 | 1.422B |
| May 17, 2024 | 1.367B |
| May 16, 2024 | 1.407B |
| May 15, 2024 | 1.417B |
| May 14, 2024 | 1.394B |
| May 13, 2024 | 1.357B |
| May 10, 2024 | 1.336B |
| May 09, 2024 | 1.544B |
| May 08, 2024 | 1.550B |
| May 07, 2024 | 1.525B |
| May 06, 2024 | 1.516B |
| May 03, 2024 | 1.532B |
| May 02, 2024 | 1.532B |
| May 01, 2024 | 1.541B |
| April 30, 2024 | 1.513B |
| April 29, 2024 | 1.506B |
| April 26, 2024 | 1.496B |
| April 25, 2024 | 1.477B |
| April 24, 2024 | 1.465B |
| April 23, 2024 | 1.481B |
| April 22, 2024 | 1.441B |
| Date | Value |
|---|---|
| April 19, 2024 | 1.445B |
| April 18, 2024 | 1.442B |
| April 17, 2024 | 1.464B |
| April 16, 2024 | 1.463B |
| April 15, 2024 | 1.454B |
| April 12, 2024 | 1.473B |
| April 11, 2024 | 1.495B |
| April 10, 2024 | 1.548B |
| April 09, 2024 | 1.574B |
| April 08, 2024 | 1.594B |
| April 05, 2024 | 1.613B |
| April 04, 2024 | 1.590B |
| April 03, 2024 | 1.595B |
| April 02, 2024 | 1.561B |
| April 01, 2024 | 1.577B |
| March 31, 2024 | 1.575B |
| March 28, 2024 | 1.626B |
| March 27, 2024 | 1.695B |
| March 26, 2024 | 1.633B |
| March 25, 2024 | 1.640B |
| March 22, 2024 | 1.626B |
| March 21, 2024 | 1.624B |
| March 20, 2024 | 1.596B |
| March 19, 2024 | 1.570B |
| March 18, 2024 | 1.614B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
202.30M
Minimum
Jul 22 2019
1.695B
Maximum
Mar 27 2024
954.02M
Average
915.58M
Median
Enterprise Value Benchmarks
| Inotiv Inc | 399.88M |
| Catalyst Pharmaceuticals Inc | 1.564B |
| Supernus Pharmaceuticals Inc | 1.215B |
| Aquestive Therapeutics Inc | 212.16M |
| NovaBay Pharmaceuticals Inc | 5.655M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 27.71M |
| Revenue (Quarterly) | 144.92M |
| Total Expenses (Quarterly) | 95.45M |
| EPS Diluted (Quarterly) | 0.71 |
| Gross Profit Margin (Quarterly) | 63.11% |
| Profit Margin (Quarterly) | 19.12% |
| Earnings Yield | 7.04% |
| Operating Earnings Yield | 11.91% |
| Normalized Earnings Yield | 7.036 |